Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's Disease Consortium survey

Kristian S. Frederiksen (Lead / Corresponding author), Thomas R. Nielsen, Ildebrando Appollonio, Birgitte Bo Andersen, Mario Riverol, Mercè Boada, Mathieu Ceccaldi, Bruno Dubois, Sebastiaan Engelborghs, Lutz Frölich, Lucrezia Hausner, Audrey Gabelle, Tomasz Gabryelewicz, Timo Grimmer, Bernard Hanseeuw, Jakub Hort, Jacques Hugon, Vesna Jelic, Anne Koivisto, Milica G. KrambergerThibaud Lebouvier, Alberto Lleó, Alexandre de Mendonça, Flavio Nobili, Pierre-Jean Ousset, Robert Perneczky, Marcel Olde Rikkert, David Robinson, Olivier Rouaud, Elisabet Sánchez, Isabel Santana, Nikolaos Scarmeas, Katerina Sheardova, Stephanie Sloan, Luiza Spiru, Elka Stefanova, Latchezar Traykov, Görsev Yener, Gunhild Waldemar

Research output: Contribution to journalArticle

Abstract

Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow-up in European expert centers diagnosing patients with MCI.

Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI.

Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI.

Conclusions: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning.

Original languageEnglish
Number of pages10
JournalInternational Journal of Geriatric Psychiatry
Early online date7 Sep 2020
DOIs
Publication statusE-pub ahead of print - 7 Sep 2020

Keywords

  • mild cognitive impairment
  • dementia
  • diagnostic disclosure
  • biomarker counselling
  • biomarkers
  • Alzheimer's disease
  • survey
  • diagnosis
  • biomarker counseling

Fingerprint Dive into the research topics of 'Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's Disease Consortium survey'. Together they form a unique fingerprint.

  • Cite this

    Frederiksen, K. S., Nielsen, T. R., Appollonio, I., Andersen, B. B., Riverol, M., Boada, M., Ceccaldi, M., Dubois, B., Engelborghs, S., Frölich, L., Hausner, L., Gabelle, A., Gabryelewicz, T., Grimmer, T., Hanseeuw, B., Hort, J., Hugon, J., Jelic, V., Koivisto, A., ... Waldemar, G. (2020). Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's Disease Consortium survey. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.5427